Multiple myeloma depth of response to therapy at different stages
How important is understanding the tumour microenvironment in treating CLL?
Results of KEYNOTE-023 and pembrolizumab plus pomalidomide trials for multiple myeloma
Jesús San Miguel
Building genetic assessments into how we determine prognosis of ALL
The combination of BGB-3111 and obinutuzumab for follicular lymphoma: promising preliminary results